Christoph Kimmich | oneAMYLOIDOSISvoice

Published: Oct 14, 2020

Category

Christoph Kimmich is a hematologist and oncologist in the Department of Internal Medicine V-Hematology, Oncology, and Rheumatology at Heidelberg University. His skills and expertise focus on amyloid, amyloid neuropathies, chemotherapy, protein folding, protein aggregation, renal, clinical oncology, and multiple myeloma.

Representative Publications:

Localized Immunoglobulin Light Chain Amyloidosis: Novel Insights Including Prognostic Factors for Local Progression

CT Features in Amyloidosis of the Respiratory System - Comprehensive Analysis in a Tertiary Referral Center Cohort

Daratumumab for Systemic AL Amyloidosis: Prognostic Factors and Adverse Outcome With Nephrotic-Range Albuminuria

Prognostic Impact of Cytogenetic Aberrations in AL Amyloidosis Patients After High-Dose Melphalan: A Long-Term Follow-Up Study

Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-Gallate

First Name

Christoph

Last Name

Kimmich

Address

Department of Internal Medicine V-Hematology,<br>
Oncology and Rheumatology<br>
Heidelberg University<br>
Hauptstrasse 240